Phase 2 HexAgon trial shows higher response rate with INBRX-106 plus pembrolizumab
Inhibrx reported primary endpoint results from a randomized Phase 2 HexAgon study of INBRX-106 with pembrolizumab in first-line HNSCC.
The combination delivered a clearer treatment benefit than pembrolizumab alone, with deeper responses and longer disease control in the interim analysis.
Benefits were strongest in HPV+ disease, supporting a sharper commercial and regulatory focus on that subgroup.
The company plans a Phase 2 expansion of about 50 additional HPV+ OPSCC patients to support a potential accelerated approval pathway.
A Phase 3 confirmatory trial is planned following FDA alignment on the expanded Phase 2 framework.
INBX•
